The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience

Chad Gier; Ian Gilchrist; Matthew Fordham; Luke Riordan; Ella Milchan; Nidhi Patel; Azad Mojahedi; Sahana Choudhury; Tara Kits; Regina Cohen; Joseph Doughtery; John P Reilly; Andreas Kalogeropoulos; Tahmid Rahman; On Chen

doi:10.3389/fcvm.2024.1284562

The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience

Front Cardiovasc Med. 2024 Jan 25:11:1284562. doi: 10.3389/fcvm.2024.1284562. eCollection 2024.

Authors

Affiliations

¹ Stony Brook Heart Institute, Stony Brook University Hospital, Stony Brook, NY, United States.
² Stony Brook Renaissance School of Medicine, Stony Brook, NY, United States.

Abstract

Dyslipidemia is a leading contributor to atherosclerotic cardiovascular disease (ASCVD). There has been a significant improvement in the treatment of dyslipidemia in the past 10 years with the development of new pharmacotherapies. The intent of this review is help enhance clinicians understanding of non-statin lipid lowering therapies in accordance with the 2022 American College of Cardiology Expert Consensus Clinical Decision Pathway on the Role of Non-statin Therapies for LDL-Cholesterol Lowering. We also present a single-center experience implementing a systematic inpatient protocol for lipid lowering therapy for secondary prevention of ASCVD.

Keywords: ASCVD; LDL—Cholesterol; hyperlipidemia; lipid lower medications; quality improvement.

Publication types

Review

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.